Beijing Tiantan Biological Products (SHSE:600161) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Beijing Tiantan Biological Products LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Beijing Tiantan Biological Products's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Beijing Tiantan Biological Products's long-term debt to total assets ratio increased from Dec. 2023 (0.00) to Dec. 2024 (0.00). It may suggest that Beijing Tiantan Biological Products is progressively becoming more dependent on debt to grow their business.

Beijing Tiantan Biological Products LT-Debt-to-Total-Asset Historical Data

The historical data trend for Beijing Tiantan Biological Products's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Tiantan Biological Products LT-Debt-to-Total-Asset Chart

Beijing Tiantan Biological Products Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.07

0.03

0.02

Beijing Tiantan Biological Products Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Beijing Tiantan Biological Products LT-Debt-to-Total-Asset Calculation

Beijing Tiantan Biological Products's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	44.855	/	15869.522
	=	0.00

Beijing Tiantan Biological Products's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	44.855	/	15869.522
	=	0.00

Beijing Tiantan Biological Products (SHSE:600161) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Beijing Tiantan Biological Products LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Beijing Tiantan Biological Products's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Tiantan Biological Products Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Tiantan Biological Products Corp Ltd (SHSE:600161) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6, Boxing 2nd Road, Room 521, Building 8, Beijing Economic and Technological Development Zone, Beijing, CHN, 100024

Website

https://www.tiantanbio.com

Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business.

Executives

Zhang Yi	senior management
Ci Xiang	senior management
Fu Dao Xing	Directors, senior managers
Hu Li Gang	Director
Yang Hui Chuan	Director
Liu Ya Na	Directors, senior managers
He Yan Lin	Directors, senior managers
Wang Jian Ming	Supervisors
Wu Zhen Shan	senior management

Beijing Tiantan Biological Products Headlines

No Headlines